TABLE 1.
Recent Works Constructing Ferroptosis-related lncRNA Risk Score Models in GC patients.
| Title | Risk score (RS) model | Hybrid model | Reference | |||
|---|---|---|---|---|---|---|
| Number of lncRNAs | AUCs | Significance | Components | AUCs | ||
| Construction of a ferroptosis-related lncRNA-based model to improve the prognostic evaluation of gastric cancer patients based on bioinformatics | 17 | 0.750 for total OS | High-RS patients exhibited worse OS | Risk score | Not mentioned | Pan et al., (2021) |
| Risk level | ||||||
| T stage | ||||||
| N stage | ||||||
| M stage | ||||||
| Age | ||||||
| Gender | ||||||
| Histological; Grade | ||||||
| A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer | 4 | 0.636 for total OS | High-RS patients exhibited worse OS; the four lncRNAs were validated to be aberrantly expressed in GC tumor tissues by RT-qPCR | Individual expression level of three lncRNAs; Risk score | Not mentioned | Wei et al, (2021) |
| A ferroptosis-related lncRNAs signature predicts prognosis and therapeutic response of gastric cancer | 17 | 0.811 for total OS; 0.809 for 1-year OS; 0.805 for 3-year OS; 0.776 for 5-year OS | High-RS patients exhibited worse OS, higher tumorigenic events, lower gene mutation rates, and decreased sensitivity to anti-PD-L1 treatment; analysis in pan-cancer cell lines revealed that the RS was associated with IC50s of 41 anti-tumor drugs | Not constructed | Xiao et al, (2021) | |
| Establishment and validation of a ferroptosis-related long non-coding RNA signature for predicting the prognosis of stomach Adenocarcinoma | 3 | 0.660 for 3-year OS; 0.756 for 5-year OS | High-RS patients exhibited worse OS, advanced TNM stages, and increased tumorigenic events; the three lncRNAs were validated to be aberrantly expressed in GC cell lines by RT-qPCR | Risk score; TNM stage; age; gender | 0.635 for 3-year OS; 0.661 for 5-year OS | Zhang et al., (2022) |